Summary
Zoetis Inc. (ZTS) announced a significant leadership transition within its Research & Development (R&D) division. Dr. Catherine Knupp, the current Executive Vice President and President of R&D, will retire effective December 31, 2021. Dr. Knupp will continue to support the company in an advisory role through February 28, 2022, to ensure a smooth handover of her responsibilities. To fill this critical role, Zoetis has appointed Dr. Robert J. Polzer as the new Executive Vice President and President of R&D, effective January 1, 2022. Dr. Polzer, currently the Senior Vice President of Global Therapeutics, brings extensive experience to lead the company's innovation efforts. This transition is a key event for investors to monitor as R&D leadership is crucial for Zoetis's future pipeline and product development.
Key Highlights
- 1Dr. Catherine Knupp, EVP and President of R&D, is retiring effective December 31, 2021.
- 2Dr. Knupp will serve as an advisor to assist with the transition from January 1, 2022, to February 28, 2022.
- 3Dr. Robert J. Polzer has been appointed as the successor to Dr. Knupp, effective January 1, 2022.
- 4Dr. Polzer currently holds the position of Senior Vice President of Global Therapeutics.
- 5The company issued a press release on October 18, 2021, detailing these leadership changes.
- 6The R&D function is critical for Zoetis's long-term growth and innovation.